Verastem (VSTM) Accounts Payables (2011 - 2026)
Verastem (VSTM) posted quarterly Accounts Payables of $9.6 million for Q1 2026, up 33.38% year-over-year from $7.2 million in Q1 2025, and down 22.86% quarter-over-quarter from $12.4 million in Q4 2025.
Analysis
Verastem (VSTM) Accounts Payables (2011 - 2026) Analysis & Trends
Verastem's Accounts Payables history runs 16 years deep, the most recent figure standing at $9.6 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 33.38% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $9.6 million (up 33.38% YoY), while the FY2025 annual figure was $12.4 million, up 209.19% from the prior year.
- Accounts Payables for Q1 2026 stood at $9.6 million, down from $12.4 million in the prior quarter.
- The five-year high for Accounts Payables was $12.4 million in Q4 2025, with the low at $1.7 million in Q2 2022.
- The 5-year median for Accounts Payables is $5.4 million (2022), against an average of $6.3 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 736.04% in 2022, then tumbled 43.96% in 2024.
- Verastem's Accounts Payables stood at $4.9 million in 2022, then soared by 46.58% to $7.2 million in 2023, then sank by 43.96% to $4.0 million in 2024, then jumped by 209.19% to $12.4 million in 2025, then dropped by 22.86% to $9.6 million in 2026.
- Business Quant data shows VSTM's Accounts Payables at $9.6 million in Q1 2026, $12.4 million in Q4 2025, and $9.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 18.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.00 Mn |
| Mar 31, 2026 | 9.60 Mn |
| Dec 31, 2025 | 12.45 Mn |
| Sep 30, 2025 | 9.89 Mn |
| Jun 30, 2025 | 8.05 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 6.68 Mn |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 7.18 Mn |
| Sep 30, 2023 | 5.12 Mn |
| Jun 30, 2023 | 4.55 Mn |
| Mar 31, 2023 | 4.90 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Sep 30, 2022 | 5.36 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 2.90 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 641,000.00 |